Drug Profile
Research programme: TGF-beta antisense oligonucleotides - Isarna Therapeutics
Alternative Names: ASPH-0047; ASPH-1047; ASPH-1106; ISTH0047Latest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator Isarna Therapeutics
- Class Antifibrotics; Antiglaucomas; Antineoplastics; Antisense oligonucleotides; Hepatoprotectants
- Mechanism of Action Left right-determination factor inhibitors; Transforming growth factor beta1 inhibitors; Transforming growth factor beta2 inhibitors; Transforming growth factor beta3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Fibrosis; Glaucoma; Non-alcoholic steatohepatitis
Most Recent Events
- 16 May 2023 Preclinical trials in Non-alcoholic steatohepatitis in Germany, prior to May 2023 (Parenteral) (Isarna Therapeutics pipeline, May 2023)
- 27 Mar 2023 Research programme is still in preclinical studies for Cancer, Glaucoma and Fibrosis in Germany (Isarna therapeutics pipeline, March 2023)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)